{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:28:24Z","timestamp":1793834904882,"version":"4.6.1"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T00:00:00Z","timestamp":1706572800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006313","name":"Barncancerfonden","doi-asserted-by":"publisher","award":["BCF2017-0083"],"award-info":[{"award-number":["BCF2017-0083"]}],"id":[{"id":"10.13039\/501100006313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["4\u2013258\/2021"],"award-info":[{"award-number":["4\u2013258\/2021"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["2022-02449"],"award-info":[{"award-number":["2022-02449"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001729","name":"Swedish Foundation for Strategic Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001729","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018713","name":"CIMED","doi-asserted-by":"publisher","award":["FoUI-976434"],"award-info":[{"award-number":["FoUI-976434"]}],"id":[{"id":"10.13039\/501100018713","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.intimp.2024.111584","type":"journal-article","created":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T02:18:50Z","timestamp":1707963530000},"page":"111584","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Tumor cell derived osteopontin and prostaglandin E2 synergistically promote the expansion of myeloid derived suppressor cells during the tumor immune escape phase"],"prefix":"10.1016","volume":"129","author":[{"given":"Doste R","family":"Mamand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safa","family":"Bazaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dara K.","family":"Mohammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osama","family":"Saher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar P.B.","family":"Wiklander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behnam","family":"Sadeghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moustapha","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"EL-Andaloussi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuchehr","family":"Abedi-Valugerdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.intimp.2024.111584_b0005","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/ni1102-991","article-title":"Cancer immunoediting: from immunosurveillance to tumor escape","volume":"3","author":"Dunn","year":"2002","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2024.111584_b0010","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1146\/annurev.immunol.22.012703.104803","article-title":"The Three Es of Cancer Immunoediting","volume":"22","author":"Dunn","year":"2004","journal-title":"Annu. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2024.111584_b0015","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1600-065X.1971.tb00461.x","article-title":"Immunological Surveillance in Neoplasia","volume":"7","author":"Burnet","year":"1971","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.intimp.2024.111584_b0020","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.coi.2014.01.004","article-title":"New insights into cancer immunoediting and its three component phases\u2014elimination, equilibrium and escape","volume":"27","author":"Mittal","year":"2014","journal-title":"Curr. Opin. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2024.111584_b0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2567.2007.02587.x","article-title":"Cancer immunoediting from immune surveillance to immune escape","volume":"121","author":"Kim","year":"2007","journal-title":"Immunology"},{"issue":"6024","key":"10.1016\/j.intimp.2024.111584_b0030","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1126\/science.1203486","article-title":"Cancer Immunoediting: Integrating Immunity\u2019s Roles in Cancer Suppression and Promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.intimp.2024.111584_b0035","doi-asserted-by":"crossref","unstructured":"M. J. Smyth, G. P. Dunn, and R. D. B. T.-A. in I. Schreiber, \u201cCancer Immunosurveillance and Immunoediting: The Roles of Immunity in Suppressing Tumor Development and Shaping Tumor Immunogenicity,\u201d in Cancer Immunotherapy, vol. 90, Academic Press, 2006, pp. 1\u201350.","DOI":"10.1016\/S0065-2776(06)90001-7"},{"key":"10.1016\/j.intimp.2024.111584_b0040","doi-asserted-by":"crossref","unstructured":"T. M. Grzywa, M. Justyniarska, D. Nowis, and J. Golab, \u201cTumor Immune Evasion Induced by Dysregulation of Erythroid Progenitor Cells Development,\u201d Cancers, vol. 13, no. 4. 2021, doi: 10.3390\/cancers13040870.","DOI":"10.3390\/cancers13040870"},{"key":"10.1016\/j.intimp.2024.111584_b0045","doi-asserted-by":"crossref","unstructured":"M. Krishnamoorthy, L. Gerhardt, and S. Maleki Vareki, \u201cImmunosuppressive Effects of Myeloid-Derived Suppressor Cells in Cancer and Immunotherapy,\u201d Cells, vol. 10, no. 5. 2021, doi: 10.3390\/cells10051170.","DOI":"10.3390\/cells10051170"},{"issue":"1","key":"10.1016\/j.intimp.2024.111584_b0050","article-title":"Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer","volume":"6","author":"Li","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.intimp.2024.111584_b0055","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.intimp.2017.04.006","article-title":"Differential effects of low-dose fludarabine or 5-fluorouracil on the tumor growth and myeloid derived immunosuppression status of tumor-bearing mice","volume":"47","author":"Abedi-Valugerdi","year":"2017","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2024.111584_b0060","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.intimp.2016.08.023","article-title":"Suppressive effects of low-dose 5-fluorouracil, busulfan or treosulfan on the expansion of circulatory neutrophils and myeloid derived immunosuppressor cells in tumor-bearing mice","volume":"40","author":"Abedi-Valugerdi","year":"2016","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2024.111584_b0065","unstructured":"O. E. Lema, J. Y. Carter, P. A. Arube, C. G. Munafu, M. W. Wangai, and P. H. Rees, \u201cEvaluation of the alkaline haematin D-575 method for haemoglobin estimation in east Africa.,\u201d Bull. World Health Organ., vol. 72, no. 6, pp. 937\u2013941, 1994, [Online]. Available: https:\/\/iris.who.int\/handle\/10665\/264066."},{"issue":"9","key":"10.1016\/j.intimp.2024.111584_b0070","doi-asserted-by":"crossref","first-page":"3859","DOI":"10.3390\/cimb44090265","article-title":"Assessment of T Cell Receptor Complex Expression Kinetics in Natural Killer Cells","volume":"44","author":"Rasul","year":"2022","journal-title":"Current Issues in Molecular Biology"},{"issue":"7","key":"10.1016\/j.intimp.2024.111584_b0075","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2005-03-0979","article-title":"A two-step induction of indoleamine 2,3 dioxygenase (IDO) activity during dendritic-cell maturation","volume":"106","author":"Braun","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2024.111584_b0080","doi-asserted-by":"crossref","DOI":"10.3892\/ijo.29.2.437","article-title":"Pioglitazone inhibits the growth of human leukemia cell lines and primary leukemia cells while sparing normal hematopoietic stem cells","author":"Saiki","year":"2006","journal-title":"Int J Oncol"},{"issue":"22","key":"10.1016\/j.intimp.2024.111584_b0085","doi-asserted-by":"crossref","first-page":"6705","DOI":"10.1158\/0008-5472.CAN-14-1482","article-title":"Tumor-Derived Osteopontin Suppresses Antitumor Immunity by Promoting Extramedullary Myelopoiesis","volume":"74","author":"Kim","year":"2014","journal-title":"Cancer Res."},{"issue":"13","key":"10.1016\/j.intimp.2024.111584_b0090","doi-asserted-by":"crossref","first-page":"6638","DOI":"10.1158\/0008-5472.CAN-06-0661","article-title":"The Crucial Role of Cyclooxygenase-2 in Osteopontin-Induced Protein Kinase C \u03b1\/c-Src\/I\u03baB Kinase \u03b1\/\u03b2\u2013Dependent Prostate Tumor Progression and Angiogenesis","volume":"66","author":"Jain","year":"2006","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.intimp.2024.111584_b0095","doi-asserted-by":"crossref","first-page":"4507","DOI":"10.1158\/0008-5472.CAN-06-4174","article-title":"Prostaglandin E2 Promotes Tumor Progression by Inducing Myeloid-Derived Suppressor Cells","volume":"67","author":"Sinha","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.intimp.2024.111584_b0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/470458","article-title":"Interleukin-17 and Its Implication in the Regulation of Differentiation and Function of Hematopoietic and Mesenchymal Stem Cells","volume":"2015","author":"Mojsilovi\u0107","year":"2015","journal-title":"Mediators Inflamm."},{"key":"10.1016\/j.intimp.2024.111584_b0105","doi-asserted-by":"crossref","unstructured":"D. Cenariu et al., \u201cExtramedullary Hematopoiesis of the Liver and Spleen,\u201d Journal of Clinical Medicine, vol. 10, no. 24. 2021, doi: 10.3390\/jcm10245831.","DOI":"10.3390\/jcm10245831"},{"key":"10.1016\/j.intimp.2024.111584_b0110","doi-asserted-by":"crossref","unstructured":"Y. Bao, Z. Liu, M. Guo, B. Li, X. Sun, and L. Wang, \u201cExtramedullary hematopoiesis secondary to malignant solid tumors: a case report and literature review,\u201d Cancer Manag. Res., vol. 10, no. null, pp. 1461\u20131470, Jun. 2018, doi: 10.2147\/CMAR.S161746.","DOI":"10.2147\/CMAR.S161746"},{"issue":"8","key":"10.1016\/j.intimp.2024.111584_b0115","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1172\/JCI97973","article-title":"Spleen mediates a distinct hematopoietic progenitor response supporting tumor-promoting myelopoiesis","volume":"128","author":"Wu","year":"2018","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.intimp.2024.111584_b0120","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0008-8749(84)90138-2","article-title":"Changes in splenic histology and cytology in mice bearing plasmacytomas","volume":"87","author":"Berman","year":"1984","journal-title":"Cell. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2024.111584_b0125","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/ijc.2910120306","article-title":"The stimulatory effects of bearing primary methylcholanthrene-induced tumors upon the murine lymphoreticular system","volume":"12","author":"Smith","year":"1973","journal-title":"Int. J. Cancer"},{"issue":"8","key":"10.1016\/j.intimp.2024.111584_b0130","first-page":"1878","article-title":"The Effects of Tumor Bearing upon Changes in Cell Distribution and Membrane Antigen Characteristics in Murine Spleen and Thymus Cell Subpopulations1","volume":"33","author":"Konda","year":"1973","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.intimp.2024.111584_b0135","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/0014-2964(80)90050-X","article-title":"Changes in spleen morphology and lymphoid cell activity during tumor progression","volume":"16","author":"Yamagishi","year":"1980","journal-title":"Eur. J. Cancer"},{"issue":"2","key":"10.1016\/j.intimp.2024.111584_b0140","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/jcp.24441","article-title":"Regulation of Cellular Processes by Interleukin-16 in Homeostasis and Cancer","volume":"229","author":"Richmond","year":"2014","journal-title":"J. Cell. Physiol."},{"issue":"1","key":"10.1016\/j.intimp.2024.111584_b0145","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3109\/08977190109001076","article-title":"Effect of IL-17 on In Vitro Hematopoietic Progenitor Cells Growth and Cytokine Release in Normal and Post-irradiated Murine Bone Marrow","volume":"19","author":"Jov\u010di","year":"2001","journal-title":"Growth Factors"},{"key":"10.1016\/j.intimp.2024.111584_b0150","doi-asserted-by":"crossref","unstructured":"E. V Meehan and K. Wang, \u201cInterleukin-17 Family Cytokines in Metabolic Disorders and Cancer,\u201d Genes, vol. 13, no. 9. 2022, doi: 10.3390\/genes13091643.","DOI":"10.3390\/genes13091643"},{"issue":"4","key":"10.1016\/j.intimp.2024.111584_b0155","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/cmi.2017.107","article-title":"The unique structural and functional features of CXCL12","volume":"15","author":"Janssens","year":"2018","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.intimp.2024.111584_b0160","doi-asserted-by":"crossref","unstructured":"R. Mezzapelle et al., \u201cCXCR4\/CXCL12 Activities in the Tumor Microenvironment and Implications for Tumor Immunotherapy,\u201d Cancers, vol. 14, no. 9. 2022, doi: 10.3390\/cancers14092314.","DOI":"10.3390\/cancers14092314"},{"key":"10.1016\/j.intimp.2024.111584_b0165","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.gene.2017.10.015","article-title":"The role of CXCL12 in tumor microenvironment","volume":"641","author":"Meng","year":"2018","journal-title":"Gene"},{"issue":"3","key":"10.1016\/j.intimp.2024.111584_b0170","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-018-0391-6","article-title":"The role of osteopontin in the progression of solid organ tumour","volume":"9","author":"Zhao","year":"2018","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.intimp.2024.111584_b0175","doi-asserted-by":"crossref","unstructured":"H. R. Moorman, D. Poschel, J. D. Klement, C. Lu, P. S. Redd, and K. Liu, \u201cOsteopontin: A Key Regulator of Tumor Progression and Immunomodulation,\u201d Cancers, vol. 12, no. 11. 2020, doi: 10.3390\/cancers12113379.","DOI":"10.3390\/cancers12113379"},{"issue":"8","key":"10.1016\/j.intimp.2024.111584_b0180","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1517\/14728222.2014.925447","article-title":"Osteopontin as a therapeutic target for cancer","volume":"18","author":"Bandopadhyay","year":"2014","journal-title":"Expert Opin. Ther. Targets"},{"issue":"12","key":"10.1016\/j.intimp.2024.111584_b0185","doi-asserted-by":"crossref","first-page":"5549","DOI":"10.1172\/JCI123360","article-title":"An osteopontin\/CD44 immune checkpoint controls CD8+ T cell activation and tumor immune evasion","volume":"128","author":"Klement","year":"2018","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.intimp.2024.111584_b0190","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1172\/JCI121266","article-title":"Osteopontin mediates glioblastoma-associated macrophage infiltration and is a potential therapeutic target","volume":"129","author":"Wei","year":"2019","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.intimp.2024.111584_b0195","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.yexcr.2017.08.028","article-title":"Upregulation of PD-L1 by SPP1 mediates macrophage polarization and facilitates immune escape in lung adenocarcinoma","volume":"359","author":"Zhang","year":"2017","journal-title":"Exp. Cell Res."},{"issue":"18","key":"10.1016\/j.intimp.2024.111584_b0200","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1038\/onc.2013.184","article-title":"Osteopontin signaling upregulates cyclooxygenase-2 expression in tumor-associated macrophages leading to enhanced angiogenesis and melanoma growth via \u03b19\u03b21 integrin","volume":"33","author":"Kale","year":"2014","journal-title":"Oncogene"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924001024?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924001024?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T04:46:33Z","timestamp":1769229993000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576924001024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":40,"alternative-id":["S1567576924001024"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.111584","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tumor cell derived osteopontin and prostaglandin E2 synergistically promote the expansion of myeloid derived suppressor cells during the tumor immune escape phase","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.111584","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"111584"}}